Over the coming months, thousands of participants in Greater Manchester who enrolled on the NHS-Galleri trial in 2021 will be returning to mobile clinics for their last of three appointments for the trial.
Participants will be asked to give a blood sample to help the NHS see if using the Galleri® blood test alongside existing cancer screening can help detect cancer early. Finding cancer early often means it is easier to treat.
Around 20,000 people in Greater Manchester are preparing to take part in the final year of the NHS Galleri trial.
Since the NHS-Galleri trial first arrived in Greater Manchester in October 2021 the trial has successfully enrolled over 140,000 volunteers from many different socio-economic and ethnic backgrounds across England, including 20,000 from the Greater Manchester.
Volunteers were all aged 50 to 77 years old at the point of enrolling onto the trial and had not been diagnosed or treated for cancer in the last three years.
Alison Armstrong, Associate Director at Greater Manchester Cancer Alliance, said: “We are delighted to be welcoming back volunteers to Greater Manchester for their last trial appointments. Even if you missed your appointment last year, your involvement this year will still help with this research.”
Sarah Price, Chief Officer for Population and Health Inequalities at NHS Greater Manchester Integrated Care, said: “We are truly grateful for the ongoing support of volunteers in Greater Manchester.
“This trial continues to put the NHS at the forefront of cutting-edge research and technology. If this trial is a success, the Galleri blood test could play a major part in achieving the NHS Long Term Plan ambition to diagnose three quarters of cancers at an early stage when it is easier to treat.”
If early trial results are promising, the NHS may decide to pilot the delivery of the test to a further 1 million people.
Early research has shown that the Galleri test could help to detect cancers that are typically difficult to identify early – such as head and neck, bowel, lung, pancreatic, and throat cancers.
The test works by analysing chemical patterns in fragments of DNA that are shed from tumours into the bloodstream.
The NHS-Galleri trial is being run by The Cancer Research UK and King’s College London Cancer Prevention Trials Unit in partnership with the NHS and healthcare company, GRAIL, which has developed the Galleri test.
The trial is operating with the support of eight NHS Cancer Alliances across England that span Cheshire and Merseyside, Greater Manchester, the North East and North Cumbria, West Midlands, East Midlands, East of England, Kent and Medway, and South East London.
